BR112012002596A2 - formulações de polipeptídeo concentradas com viscodidade reduzida - Google Patents
formulações de polipeptídeo concentradas com viscodidade reduzidaInfo
- Publication number
- BR112012002596A2 BR112012002596A2 BR112012002596A BR112012002596A BR112012002596A2 BR 112012002596 A2 BR112012002596 A2 BR 112012002596A2 BR 112012002596 A BR112012002596 A BR 112012002596A BR 112012002596 A BR112012002596 A BR 112012002596A BR 112012002596 A2 BR112012002596 A2 BR 112012002596A2
- Authority
- BR
- Brazil
- Prior art keywords
- low viscous
- polypeptide formulations
- concentrated polypeptide
- viscous concentrated
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23114009P | 2009-08-04 | 2009-08-04 | |
| PCT/US2010/044258 WO2011017330A1 (en) | 2009-08-04 | 2010-08-03 | Concentrated polypeptide formulations with reduced viscosity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002596A2 true BR112012002596A2 (pt) | 2015-09-15 |
Family
ID=43544629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002596A BR112012002596A2 (pt) | 2009-08-04 | 2010-08-03 | formulações de polipeptídeo concentradas com viscodidade reduzida |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130236448A1 (https=) |
| EP (1) | EP2461677A4 (https=) |
| JP (1) | JP2013501058A (https=) |
| KR (1) | KR20120047995A (https=) |
| CN (1) | CN102573459A (https=) |
| AU (1) | AU2010279569A1 (https=) |
| BR (1) | BR112012002596A2 (https=) |
| CA (1) | CA2769221A1 (https=) |
| IL (1) | IL217887A0 (https=) |
| MX (1) | MX2012001560A (https=) |
| NZ (1) | NZ598518A (https=) |
| RU (1) | RU2012108108A (https=) |
| SG (1) | SG178226A1 (https=) |
| WO (1) | WO2011017330A1 (https=) |
| ZA (1) | ZA201200760B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CN107837395A (zh) | 2011-02-09 | 2018-03-27 | 葛兰素史密斯克莱有限责任公司 | 冻干制剂 |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| JP7156777B2 (ja) * | 2013-11-29 | 2022-10-19 | ジェネンテック， インコーポレイテッド | 抗体選択装置及び方法 |
| WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002182A2 (en) * | 1997-07-10 | 1999-01-21 | Biotech Australia Pty. Limited | Non-aqueous vaccines |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| WO2004001007A2 (en) * | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Buffered formulations for concentrating antibodies and methods of use thereof |
| US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| WO2005117830A1 (en) * | 2004-06-04 | 2005-12-15 | Camurus Ab | Liquid depot formulations |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| CN1968961A (zh) * | 2004-06-14 | 2007-05-23 | Usv有限公司 | 制备肽的方法 |
| ES2365410T3 (es) * | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
-
2010
- 2010-08-03 RU RU2012108108/15A patent/RU2012108108A/ru not_active Application Discontinuation
- 2010-08-03 CA CA2769221A patent/CA2769221A1/en not_active Abandoned
- 2010-08-03 JP JP2012523701A patent/JP2013501058A/ja active Pending
- 2010-08-03 EP EP10807032.7A patent/EP2461677A4/en not_active Withdrawn
- 2010-08-03 BR BR112012002596A patent/BR112012002596A2/pt not_active IP Right Cessation
- 2010-08-03 AU AU2010279569A patent/AU2010279569A1/en not_active Abandoned
- 2010-08-03 SG SG2012007399A patent/SG178226A1/en unknown
- 2010-08-03 KR KR1020127005604A patent/KR20120047995A/ko not_active Withdrawn
- 2010-08-03 US US13/388,962 patent/US20130236448A1/en not_active Abandoned
- 2010-08-03 CN CN2010800445005A patent/CN102573459A/zh active Pending
- 2010-08-03 WO PCT/US2010/044258 patent/WO2011017330A1/en not_active Ceased
- 2010-08-03 NZ NZ598518A patent/NZ598518A/en not_active IP Right Cessation
- 2010-08-03 MX MX2012001560A patent/MX2012001560A/es not_active Application Discontinuation
-
2012
- 2012-01-31 ZA ZA2012/00760A patent/ZA201200760B/en unknown
- 2012-02-02 IL IL217887A patent/IL217887A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011017330A1 (en) | 2011-02-10 |
| NZ598518A (en) | 2014-12-24 |
| CA2769221A1 (en) | 2011-02-10 |
| EP2461677A4 (en) | 2014-01-08 |
| AU2010279569A1 (en) | 2012-03-01 |
| EP2461677A1 (en) | 2012-06-13 |
| US20130236448A1 (en) | 2013-09-12 |
| WO2011017330A8 (en) | 2011-04-21 |
| MX2012001560A (es) | 2012-06-01 |
| RU2012108108A (ru) | 2013-09-10 |
| CN102573459A (zh) | 2012-07-11 |
| JP2013501058A (ja) | 2013-01-10 |
| KR20120047995A (ko) | 2012-05-14 |
| ZA201200760B (en) | 2013-05-29 |
| SG178226A1 (en) | 2012-03-29 |
| IL217887A0 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181347T1 (hr) | Formulacije dvoslojne tablete | |
| LT3061445T (lt) | Labai koncentruotos farmacinės kompozicijos | |
| HUE036081T2 (hu) | Mirac proteinek | |
| BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
| EP2504020A4 (en) | Daptomycin FORMULATIONS | |
| BRPI1006519A2 (pt) | formulação de anticorpos | |
| BRPI1013588A2 (pt) | composição | |
| BRPI1016228A2 (pt) | formulações de eletrólito compatibilizadas | |
| BR112013011472A2 (pt) | Composição de gel | |
| BRPI1015474A2 (pt) | composição | |
| BRPI1009465A2 (pt) | Formulação | |
| BR112012002596A2 (pt) | formulações de polipeptídeo concentradas com viscodidade reduzida | |
| EP2437770A4 (en) | ANTIMICROBIAL PEPTIDES | |
| BRPI0914063A2 (pt) | composição de xampu concentrado | |
| PT2635269T (pt) | Composição de combinação | |
| BRPI1009428A2 (pt) | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 | |
| EP2624836A4 (en) | BEPOTASTIN COMPOSITION | |
| EP2475251A4 (en) | STABLE HYALURONANE / STEROID FORMULATION | |
| EP2479211A4 (en) | FLUOR RUBBER COMPOSITION | |
| HUE054030T2 (hu) | Fejlesztett formulációk | |
| BRPI1005318A2 (pt) | composição | |
| BRPI1008963A2 (pt) | 2-mercapto-3-aminopiridina substituída como moduladores de kcnq2/3 | |
| EP2405745A4 (en) | HERBICIDE COMPOSITION | |
| BRPI0908455A2 (pt) | formulações de flibanserina | |
| BRPI0920833A2 (pt) | preparação de benzonorborbenos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |